I agree with the sentiments of the person who wrote this in the comments section at the bottom of the Motley Fool story the other day by some dope who said he wouldn't touch Amarin with a 10-foot pool:
I only approach stocks with 5-foot poles so I am the perfect person to comment on this. Long-term Amarin shareholders have suffered through six years of pain as U.S. revenues steadily decreased after a judge gave foreign-run vulture generics a "skinny" label that theoretically would give them a share of 7 percent of Amarin's market. But lax U.S. laws and state rules prioritizing the distribution of generic drugs, even when it means trampling on valid patents and even when the generic brand isn't much cheaper, if at all, gave generics nearly 50 percent of the U.S. market for Amarin's only drug. The worst is over, though, and the prospects for sales in dozens of countries eventually dwarfing U.S. sales means those who buy now at this low will reap a nice profit sooner than later.
Market Data 
Markets 
AI
